(MedPage Today) — The cancer drug tazemetostat (Tazverik) is being voluntarily withdrawn in the U.S. and all other markets over concerns about secondary cancers, drugmaker Ipsen announced.
The company also said it is discontinuing all active…
Source link : https://www.medpagetoday.com/hematologyoncology/lymphoma/120234
Author :
Publish date : 2026-03-09 21:30:00
Copyright for syndicated content belongs to the linked Source.
